메뉴 건너뛰기




Volumn 34, Issue 24, 2016, Pages 2925-2933

Updating the American society of clinical oncology value framework: Revisions and reflections in response to comments received

(23)  Schnipper, Lowell E a   Davidson, Nancy E d   Wollins, Dana S f   Blayney, Douglas W g   Dicker, Adam P e   Ganz, Patricia A h   Russell Hoverman, J j   Langdon, Robert k   Lyman, Gary H m   Meropol, Neal J n   Mulvey, Therese b   Newcomer, Lee o   Peppercorn, Jeffrey b   Polite, Blase p   Raghavan, Derek q   Rossi, Gregory r   Saltz, Leonard s   Schrag, Deborah c   Smith, Thomas J t   Yu, Peter P i   more..


Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

EID: 84976398620     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.2518     Document Type: Article
Times cited : (533)

References (14)
  • 1
    • 84939251874 scopus 로고    scopus 로고
    • American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options
    • Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563-2577, 2015
    • (2015) J Clin Oncol , vol.33 , pp. 2563-2577
    • Schnipper, L.E.1    Davidson, N.E.2    Wollins, D.S.3
  • 2
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 3
    • 84908575897 scopus 로고    scopus 로고
    • Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial
    • Fizazi K, Scher HI, Miller K, et al: Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15:1147-1156, 2014
    • (2014) Lancet Oncol , vol.15 , pp. 1147-1156
    • Fizazi, K.1    Scher, H.I.2    Miller, K.3
  • 4
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 5
    • 80052728749 scopus 로고    scopus 로고
    • Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
    • Perez EA, Romond EH, Suman VJ, et al: Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 3366-3373
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3
  • 6
    • 84950133717 scopus 로고    scopus 로고
    • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
    • Burger JA, Tedeschi A, Barr PM, et al: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373:2425-2437, 2015
    • (2015) N Engl J Med , vol.373 , pp. 2425-2437
    • Burger, J.A.1    Tedeschi, A.2    Barr, P.M.3
  • 7
    • 84933678156 scopus 로고    scopus 로고
    • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial
    • Eggermont AM, Chiarion-Sileni V, Grob J-J, et al: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 16:522-530, 2015
    • (2015) Lancet Oncol , vol.16 , pp. 522-530
    • Eggermont, A.M.1    Chiarion-Sileni, V.2    Grob, J.-J.3
  • 11
    • 84940648261 scopus 로고    scopus 로고
    • A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
    • Cherny NI, Sullivan R, Dafni U, et al: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547-1573, 2015
    • (2015) Ann Oncol , vol.26 , pp. 1547-1573
    • Cherny, N.I.1    Sullivan, R.2    Dafni, U.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.